ArticlePloS one2015
Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- An Indolent Enteropathy Accelerated by Combination Immune Checkpoint Inhibitor Therapy.ACG case reports journal · 2026Article
- Diagnostic clues in patients with clinical malabsorption and pathological small intestinal villous atrophy: Immune-mediated type and beyond.World journal of gastroenterology · 2026Review
- Olmesartan-associated gastroduodenitis that was detected on endoscopic follow-up.Clinical journal of gastroenterology · 2025Article
- Atypical Rapid Onset of Olmesartan-Induced Enteropathy with Recurrence After Rechallenging.Diseases (Basel, Switzerland) · 2025Article
- Cellular and molecular basis of proximal small intestine disorders.Nature reviews. Gastroenterology & hepatology · 2024Review
- Refractory Celiac Disease: What the Gastroenterologist Should Know.International journal of molecular sciences · 2024Review
- Article
- Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Article
- Olmesartan-associated Enteropathy with Acute Kidney Injury.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Article
- Acute Flare of Adult-Onset Autoimmune Enteropathy Associated With Cyclophosphamide.ACG case reports journal · 2021Article
- Pharmacy and therapeutics committees strategy to address olmesartan safety issues at a primary care level.International journal of clinical pharmacy · 2020Observational
- Article
- Association of sprue-like enteropathy and angiotensin receptor-1 antagonists.Wiener klinische Wochenschrift · 2019Review
- Autoimmune Enteropathy: An Updated Review with Special Focus on Stem Cell Transplant Therapy.Digestive diseases and sciences · 2019Review
- Recent advances in celiac disease and refractory celiac disease.F1000Research · 2019Review
- Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report.Current drug safety · 2019Article
- Case of olmesartan-associated enteropathy and transient positive antitissue transglutaminase serology.BMJ case reports · 2018Article
- Olmesartan-associated severe gastritis and enteropathy.BMJ case reports · 2018Article
- Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy.Pharmacoepidemiology and drug safety · 2018Observational
- Acute Gastrointestinal Bleeding in Olmesartan-Associated Collagenous Gastroduodenitis: A Potential Endoscopic Complication.Case reports in gastrointestinal medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAnti-hypertensive treatment with the angiotensin II receptor antagonist olmesartan is a rare cause of severe Sprue-like enteropathy. To substantiate the hypothesis that olmesartan interferes with gut immune homeostasis, clinical, histopathological and immune features were compared in olmesartan-induced-enteropathy (OIE) and in autoimmune enteropathy (AIE).
methodsMedical files of seven patients with OIE and 4 patients with AIE enrolled during the same period were retrospectively reviewed. Intestinal biopsies were collected for central histopathological review, T cell Receptor clonality and flow cytometric analysis of isolated intestinal lymphocytes.
resultsAmong seven olmesartan-treated patients who developed villous atrophy refractory to a gluten free diet, three had extra-intestinal autoimmune diseases, two had antibodies reacting with the 75 kilodalton antigen characteristic of AIE and one had serum anti-goblet cell antibodies. Small intestinal lesions and signs of intestinal lymphocyte activation were thus reminiscent of the four cases of AIE diagnosed during the same period. Before olmesartan discontinuation, remission was induced in all patients (7/7) by immunosuppressive drugs. After interruption of both olmesartan and immunosuppressive drugs in six patients, remission was maintained in 4 but anti-TNF-α therapy was needed in two.
conclusionThis case-series shows that olmesartan can induce intestinal damage mimicking AIE. OIE usually resolved after olmesartan interruption but immunosuppressive drugs may be necessary to achieve remission. Our data sustain the hypothesis that olmesartan interferes with intestinal immuno regulation in predisposed individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.